Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

NCT07694765 is registered in ClinicalTrials.gov with LaNova Medicines Limited as lead sponsor.

NCT NCT07694765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07694765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
Lead sponsor
LaNova Medicines Limited
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
December 31, 2030
Enrollment
90 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant tumors